BIO, PhRMA Back Call For Fed. Circ. To Broaden AIA Estoppel

By Ryan Davis ( February 10, 2017, 9:23 PM EST) -- Two major drug industry groups urged the Federal Circuit Thursday to expand the reach of the America Invents Act inter partes review estoppel provision, arguing that lower courts have read it too narrowly and are wrongly allowing patent challengers to relitigate invalidity arguments in court. . . .

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

This past year, a handful of attorneys secured billions of dollars in settlements and judgments for both classes and individual plaintiffs against massive companies and organizations like Facebook, Dell, the National Association of Realtors, Johnson & Johnson, UFC and Credit Suisse, earning them recognition as Law360's Titans of the Plaintiffs Bar for 2025.